Elemer Piros

bluebird bio Inc (NASDAQ: BLUE) reported compelling data over the weekend at the American Society of Hematology that some experts described as "unheard of." The Analyst Cantor Fitzgerald's Elemer Piros reiterated an Underweight on bluebird's stock with a price target...

Omeros Corporation (NASDAQ: OMER) shares are on a tear, the catalyst being the release of its third-quarter results. The Analyst Cantor Fitzgerald's Elemer Piros, Ph.D, reviewed Omeros' quarterly results. The Rating The firm maintained its Neutral rating and 12-month price target of $19...

Dynavax Technologies Corporation (NASDAQ: DVAX), a clinical-stage immunotherapy company, confirmed on Thursday the U.S. Food and Drug Administration approved its two-dose vaccine  The company failed to gain approval for its therapy in February 2013 and in November 2016. But now that the...

In the biotechnology sector, Canter Fitzgerald analyst Elemer Piros increased his price target for bluebird bio Inc (NASDAQ: BLUE) from $39 to $58, but he maintains an Underweight rating. He increased the price target following the introduction of a multiple-myeloma model to his net present value...

Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) gained 10 percent on Thursday in reaction to the company's encouraging update to a phase 2 trial of its autoimmune disease drug called anabasum. Corbus' top-line data from a 22-patient study of anabasum for the treatment of...

Analysts at Cantor Fitzgerald continue to hold a bullish stance on Spark Therapeutics Inc (NASDAQ: ONCE) after the U.S. Food and Drug Administration gave the company a critical recommendation for its therapy called Luxturna. Analyst Elemer Piros maintains an Overweight rating on Spark's stock...

Following the release of briefing documents for Aerie Pharmaceuticals Inc (NASDAQ: AERI)'s Rhopressa's upcoming Adcom meeting, Cantor Fitzgerald said the news was good, with no surprises. The Adcom meeting is scheduled on October 13, 2017. Reviewing all the data and the recent briefing documents...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) investors may have reason for cautious optimism after the company’s recent Fragile X Syndrome treatment data. On Monday, Cantor Fitzgerald analyst Elemer Piros upgraded Zynerba to Overweight and said there is a reasonable change ZYN002 will find...

Zogenix, Inc. (NASDAQ: ZGNX) shares jumped another 5.6 percent Monday morning after exploding higher by 172 percent Sept. 29 in the wake of positive data on anti-epileptic drug ZX008. Shares of GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) plummeted 9.6 percent last Friday as well, and dropped another...

Cantor Fitzgerald cut its Versartis Inc (NASDAQ: VSAR) target from $34 to $14 — and was still able to rate it Overweight. The stock dropped from $21.60 to $3.20 in Friday pre-market trading after the firm released negative Phase 3 data on its Somavaratan trial for pediatric growth hormone...

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) shares initially jumped Monday after disappointing data from a leading drug candidate sent shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) plummeting more than 55 percent. However, while GW may now have less competition in the mix, investors soon...

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), plunged 56 percent in pre-market trading after the company announced that its transdermal synthetic cannabinoid treatment for epilepsy, ZYN002, didn’t demonstrate a statistically significant reduction in median seizure frequency. Rating...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), which specializes in transdermal synthetic cannabinoid treatments, has a 25-percent probability for success in its treatment of adult epilepsy, an analyst said Tuesday. Cantor Fitzgerald analyst Elemer Piros said there were no surprises in the Q2 results...

Following Intercept Pharmaceuticals Inc (NASDAQ: ICPT)'s strong second-quarter results and meaningful Ocaliva, or OCA, revenue growth, Cantor Fitzgerald maintains its Underweight rating on the shares of the company. However, the firm raised its price target for the shares from $60 to $69. Strong Q2...

Despite a more than 20 percent plunge in Ocular Therapeutix Inc (NASDAQ: OCUL)'s stock Wednesday morning, analysts at Cantor Fitzgerald continue to see tremendous upside in the stock. Cantor Fitzgerald's Elemer Piros maintains an Overweight rating on Ocular's stock but with a price...